Real-world experience with CLAIRYG® 50 mg/mL (intravenous immunoglobulin) in children under 12 years with primary immunodeficiency or immmune thrombocytopenia: a post-approval safety study

Overview of attention for article published in Frontiers in Pediatrics, October 2023

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 3 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 3,952 followers.

New Research: Real-world experience with CLAIRYG® 50 mg/mL (intravenous immunoglobulin) in children under 12 years with primary immunodeficiency or immmune thrombocytopenia: a post-approval safety study: Introduction This study presents the… https://t.co/

27 Oct 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.